Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil-remimazolam vs. Remifentanil-remimazolam TIVA in Gastrectomy
NCT05785234Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of sufentanil in gastric cancer (GC) (2 arms), sponsored by Yonsei University. Primary endpoint: Total consumption of fentanyl in 24 hours after surgery. Status: unknown.
02
Drugs
sufentanil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05785234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785234.